Scarica l'app Stockscreener
17.99
7.12%
-1.38
Precedente Chiudi:
$19.37
Aprire:
$18.2
Volume 24 ore:
313.26K
Relative Volume:
1.20
Capitalizzazione di mercato:
$256.54M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+22.13%
1M Prestazione:
+67.04%
6M Prestazione:
-47.88%
1 anno Prestazione:
-46.65%
Intervallo 1D:
$15.68
$18.89
Intervallo di 1 settimana:
$13.93
$19.51
Portata 52W:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Nome
Neurogene Inc
Settore
Industria
Telefono
(877) 237-5020
Indirizzo
535 W 24TH STREET, NEW YORK
Confronta NGNE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
17.99 | 210.08M | 0 | 0 | 0 | 0.00 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2024-03-21 | Iniziato | William Blair | Outperform |
| 2024-01-08 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-05 | Iniziato | Stifel | Buy |
| 2024-01-04 | Iniziato | TD Cowen | Outperform |
Mostra tutto
Neurogene Inc Borsa (NGNE) Ultime notizie
Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $46.20 - Defense World
Neurogene Shares Drop After Downgrade From Baird - marketscreener.com
Neurogene stock downgraded at Baird (NGNE:NASDAQ) - Seeking Alpha
Neurogene (NGNE) Downgraded to Neutral with Lowered Price Target | NGNE Stock News - GuruFocus
Neurogene (NGNE) Presents New Protocol for Tackling Gene Therapy - GuruFocus
Neurogene presents HLH treatment strategy at ASGCT meeting - Investing.com Australia
Neurogene Announces Evidence-Based Monitoring And Treatment Intended To Reverse Rare Hyperinflammatory Syndrome Associated With High-Dose Aav - marketscreener.com
Neurogene presents HLH treatment strategy at ASGCT meeting By Investing.com - Investing.com India
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV - Eagle-Tribune
Neurogene (NGNE) Downgraded by Baird Amid Regulatory Concerns | - GuruFocus
Baird cuts Neurogene stock rating, lowers price target to $24 By Investing.com - Investing.com India
Q2 Earnings Estimate for Neurogene Issued By HC Wainwright - Defense World
Rett Syndrome treatment Market Is Booming Worldwide 2025-2032 | - openPR.com
HC Wainwright Has Lowered Expectations for Neurogene (NASDAQ:NGNE) Stock Price - Defense World
Neurogene (NGNE) Analyst Rating Update: Target Price Adjusted | - GuruFocus
Neurogene (NGNE) Target Price Reduced, Buy Rating Maintained | N - GuruFocus
Wells Fargo & Company MN Purchases 1,397 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Barclays PLC Has $401,000 Position in Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene: Q1 Earnings Snapshot - San Francisco Chronicle
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 8, 2025 - BioSpace
Neurogene Reports Q1 2025 Financial Results and Advances Rett Syndrome Gene Therapy - TipRanks
NEUROGENE Earnings Results: $NGNE Reports Quarterly Earnings - Nasdaq
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates - Business Wire
Daily Market Movement: Neurogene Inc (NGNE) Sees a -13.63 Decrease, Closing at 13.05 - DWinneX
10,475 Shares in Neurogene Inc. (NASDAQ:NGNE) Bought by Mariner LLC - Defense World
Neurogene Inc expected to post a loss of $1.06 a shareEarnings Preview - TradingView
Neurogene (NGNE) Expected to Announce Earnings on Friday - Defense World
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting - BioSpace
Neurogene Announces Upcoming Oral Presentation On Monitoring And Treatment To Reverse Rare Complication Of High Dose Gene Therapy - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Lost Money on Neurogene Inc. (NGNE)? You May Have Been Affected by FraudContact Levi & Korsinsky - ACCESS Newswire
Neurogene Inc. (NASDAQ:NGNE) Shares Acquired by Geode Capital Management LLC - Defense World
Analysts Set Neurogene Inc. (NASDAQ:NGNE) Price Target at $47.20 - Defense World
Wellington Management Group LLP Grows Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - The AM Reporter
BMO cuts Neurogene stock target to $16 from $45, keeps Outperform By Investing.com - Investing.com South Africa
Wellington Management Group LLP Increases Stock Holdings in Neurogene Inc. (NASDAQ:NGNE) - Defense World
JPMorgan Chase & Co. Purchases 476,418 Shares of Neurogene Inc. (NASDAQ:NGNE) - Defense World
Neurogene (NASDAQ:NGNE) Given New $16.00 Price Target at BMO Capital Markets - Defense World
Neurogene Inc. Amends Agreement, Issues Warrants By Investing.com - Investing.com South Africa
Neurogene Inc. Amends Agreement, Issues Warrants - Investing.com
Neurogene Amends Agreement With Baker Bros To Increase Nomination Threshold - marketscreener.com
BMO cuts Neurogene stock target to $16 from $45, keeps Outperform - Investing.com Canada
NGNE Stock Sees Decline of Approximately -13.67% in Last Five Days - knoxdaily.com
NGNE stock touches 52-week low at $8.35 amid market challenges - Investing.com Australia
NGNE stock touches 52-week low at $8.35 amid market challenges By Investing.com - Investing.com South Africa
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome - BioSpace
Neurogene reports progress in gene therapy regulation technology By Investing.com - Investing.com Canada
Neurogene Inc Azioni (NGNE) Dati Finanziari
Non sono disponibili dati finanziari per Neurogene Inc (NGNE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
7.58%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):